Neuren Pharmaceuticals CEO Jon Pilcher discusses on Phase 3 LAVENDER Rett Syndrome trial. - Jon Pilcher, BSc (Hons), FCA Chief Executive Officer/Managing Director, Neuren Pharmaceuticals Ltd 00:00:00
Jon joined Neuren in August 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010.
